CytomX Therapeutics
CTMX
68 hedge funds and large institutions have $50.7M invested in CytomX Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 3 closing their positions.
580% more call options, than puts
Call options by funds: $34K | Put options by funds: $5K
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
21% more capital invested
Capital invested by funds: $41.8M → $50.7M (+$8.93M)
10% more funds holding
Funds holding: 62 → 68 (+6)
0.33% more ownership
Funds ownership: 48.52% → 48.85% (+0.33%)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$520K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$254K |
| 3 |
CPC
Congress Park Capital
Saratoga Springs,
New York
|
+$167K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$137K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$343K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$335K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$188K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$124K |
| 5 |
Two Sigma Advisers
New York
|
-$87.7K |
CTMX Hedge Fund Activity: Q4 2023 in Review
68 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2023, worth a combined $50.7M — up 21% from $41.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CTMX positions and 3 closed out — a net gain of 6 holders — while 16 added to existing stakes and 20 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $520K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $343K.
- 68 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2023, up from 62 in Q3 2023.
- Funds reported $50.7M of CytomX Therapeutics stock for Q4 2023, up 21% quarter-over-quarter.
- 9 funds opened new CytomX Therapeutics positions in Q4 2023 and 3 closed out, a net change of +6 holders.
- The largest CytomX Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $520K added.
- The largest CytomX Therapeutics seller in Q4 2023 was Jacobs Levy Equity Management, an estimated $343K sold.
Based on aggregated 13F filings for Q4 2023.